Key Points
- Insider sale: Beth Hecht sold 16,667 Xeris (XERS) shares on March 2 at an average of $6.25 (~$104,169), reducing her stake by 1.34% to 1,226,507 shares after similar monthly sales in January and February.
- Company outlook: Xeris beat Q results with $0.06 EPS versus a $0.03 estimate (revenue $85.81M vs. $86M), and analysts maintain a "Moderate Buy" consensus with an average price target of $10.08 despite a forecasted full‑year EPS near -$0.41.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $6.25, for a total value of $104,168.75. Following the sale, the insider owned 1,226,507 shares of the company's stock, valued at $7,665,668.75. This trade represents a 1.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Beth Hecht also recently made the following trade(s):
- On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.45, for a total transaction of $124,169.15.
- On Friday, January 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.43, for a total transaction of $123,835.81.
Xeris Biopharma Stock Performance
Shares of NASDAQ:XERS traded up $0.01 during midday trading on Thursday, hitting $6.08. The stock had a trading volume of 1,012,351 shares, compared to its average volume of 2,069,536. Xeris Biopharma Holdings, Inc. has a 1 year low of $3.81 and a 1 year high of $10.08. The company has a current ratio of 2.19, a quick ratio of 1.35 and a debt-to-equity ratio of 16.10. The stock has a 50 day moving average price of $7.16 and a two-hundred day moving average price of $7.61. The company has a market capitalization of $1.05 billion, a PE ratio of -607.39 and a beta of 0.61.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Monday, March 2nd. The company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The firm had revenue of $85.81 million during the quarter, compared to the consensus estimate of $86.00 million. As a group, equities analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Xeris Biopharma
Large investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new position in shares of Xeris Biopharma in the fourth quarter worth $25,000. AlphaQuest LLC acquired a new position in Xeris Biopharma in the 3rd quarter valued at about $35,000. Caitong International Asset Management Co. Ltd lifted its holdings in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company's stock valued at $59,000 after purchasing an additional 7,421 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Xeris Biopharma by 29.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company's stock worth $63,000 after buying an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company's stock valued at $63,000 after buying an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently commented on the stock. Piper Sandler raised their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a "neutral" rating in a research note on Friday, November 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Xeris Biopharma in a research note on Wednesday, January 21st. Wall Street Zen cut Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a report on Saturday, November 8th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research note on Monday. Finally, Oppenheimer reiterated an "outperform" rating and set a $18.00 target price on shares of Xeris Biopharma in a research report on Friday, November 7th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Xeris Biopharma has a consensus rating of "Moderate Buy" and an average price target of $10.08.
View Our Latest Report on Xeris Biopharma
More Xeris Biopharma News
Here are the key news stories impacting Xeris Biopharma this week:
- Positive Sentiment: HC Wainwright reaffirmed a "Buy" rating with a $10 price target and published multi‑year upside EPS forecasts through 2030, signalling confidence in the company’s longer‑term revenue progress and pipeline potential. HC Wainwright coverage / MarketBeat
- Positive Sentiment: Several third‑party pieces, including a bullish Seeking Alpha article, argue Xeris is undervalued relative to its drug portfolio, which can attract value and growth‑oriented investors. Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio
- Positive Sentiment: Analyst consensus has been summarized as a "Moderate Buy" by market coverage services, indicating general analyst support that can underpin momentum. Consensus Rating of Moderate Buy
- Neutral Sentiment: HC Wainwright published specific quarterly estimates (Q1‑Q4 2026) including a Q1‑2026 EPS estimate of ($0.03) and a FY2026 view of $0.06 — these provide a roadmap for expected near‑term results but include mixed signs as the company transitions to profitability horizons. HC Wainwright estimates / MarketBeat
- Neutral Sentiment: Consensus full‑year EPS remains negative (around ‑$0.41), so near‑term profitability is still a risk until guidance/actuals show consistent improvement. Consensus estimates / MarketBeat
- Negative Sentiment: An insider (Beth Hecht) sold 16,667 shares at an average $6.25 on Mar 2, which may be perceived negatively by some investors as a liquidity or confidence signal. SEC filing: Insider sale Form 4
- Negative Sentiment: HC Wainwright trimmed several mid‑/long‑range EPS forecasts (FY2026‑FY2029 revisions downward), which reduces near‑term upside expectations and could temper sentiment until revenue trends validate earlier, higher projections. HC Wainwright revisions / MarketBeat
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
